{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:11:21Z","timestamp":1792239081388,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>mRNA-2416 is a novel lipid nanoparticle-encapsulated messenger RNA (mRNA) encoding human OX40 ligand (OX40L) for intratumoral (Itu) injection. OX40L plus immune checkpoint inhibitor (ICI) increased preclinical antitumor activity, thus mRNA-2416 plus ICI may potentiate antitumor activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This first-in-human, phase I\/II, open-label, multicenter study examined the safety, tolerability, and efficacy of mRNA-2416 alone (arm A) or with durvalumab (arm B) in patients with advanced solid tumors or lymphoma (NCT03323398). Phase I primary objectives included assessment of safety\/tolerability and maximum tolerated dose (MTD)\/recommended dose for expansion; phase II arm B dose expansion assessed objective response rate in ovarian cancers. Secondary objectives included pharmacokinetics, disease control rate, duration of response, and progression-free survival (PFS). Assessments of immunologic response to treatment were exploratory.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>From August 2017 to August 2021, 79 patients were enrolled; 61 received treatment (arm A: 39, arm B: 22), including 16 in the expansion cohort. MTD was not reached. Treatment-related emergent adverse events were primarily grade 1\/2, with 8 grade 3 and no grade 4\/5 events. On-treatment tumor biopsies demonstrated increased OX40L protein expression, elevated PD-L1, and proinflammatory responses. Tumor shrinkage occurred in injected and surrounding non-injected tumors. Median (95% CI) PFS was 60.0 (50.0 to 108.0) and 50.0 (38.0 to 55.0) days for arms A and B, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>mRNA-2416 alone or with durvalumab was well tolerated. Pharmacodynamic analyses support Itu mRNA proof-of-concept. Predefined primary efficacy endpoints were not met in an exploratory cohort of ovarian cancer. Additional research is warranted to further inform this therapeutic approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf115","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T05:59:03Z","timestamp":1749880743000},"source":"Crossref","is-referenced-by-count":17,"title":["First-in-human phase I\/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer"],"prefix":"10.1093","volume":"30","author":[{"given":"Ryan J","family":"Sullivan","sequence":"first","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladapo O","family":"Yeku","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Teoh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology and Women\u2019s Health, University of Minnesota Masonic Cancer Center , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-503X","authenticated-orcid":false,"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa S","family":"Laino","sequence":"additional","affiliation":[{"name":"Oncology Research and Clinical Development , Oncology, Moderna Therapeutics, Inc., Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Oncology Research and Clinical Development , Oncology, Moderna Therapeutics, Inc., Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[{"name":"Oncology Research and Clinical Development , Oncology, Moderna Therapeutics, Inc., Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Van","sequence":"additional","affiliation":[{"name":"Oncology Research and Clinical Development , Oncology, Moderna Therapeutics, Inc., Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pascarella","sequence":"additional","affiliation":[{"name":"Oncology Research and Clinical Development , Oncology, Moderna Therapeutics, Inc., Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima J","family":"Zacharek","sequence":"additional","affiliation":[{"name":"Oncology Research and Clinical Development , Oncology, Moderna Therapeutics, Inc., Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-8899","authenticated-orcid":false,"given":"Khanh T","family":"Do","sequence":"additional","affiliation":[{"name":"Oncology Research and Clinical Development , Oncology, Moderna Therapeutics, Inc., Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8560-0440","authenticated-orcid":false,"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Colorado Cancer Center , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"2025061401585573400_CIT0001","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: immune checkpoint inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell."},{"key":"2025061401585573400_CIT0002","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun."},{"key":"2025061401585573400_CIT0003","doi-asserted-by":"publisher","first-page":"100738","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl Oncol."},{"key":"2025061401585573400_CIT0004","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"2025061401585573400_CIT0005","doi-asserted-by":"publisher","first-page":"795547","DOI":"10.3389\/fonc.2021.795547","article-title":"Immunotherapy in ovarian cancer: thinking beyond PD-1\/PD-L1","volume":"11","author":"Chardin","year":"2021","journal-title":"Front Oncol."},{"key":"2025061401585573400_CIT0006","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/j.1460-2075.1990.tb08211.x","article-title":"Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor","volume":"9","author":"Mallett","year":"1990","journal-title":"EMBO J."},{"key":"2025061401585573400_CIT0007","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol Rev."},{"key":"2025061401585573400_CIT0008","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.1158\/1078-0432.CCR-21-0987","article-title":"Spatial mapping and immunomodulatory role of the OX40\/OX40L pathway in human non-small cell lung cancer","volume":"27","author":"Porciuncula","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2025061401585573400_CIT0009","doi-asserted-by":"publisher","first-page":"CT032","DOI":"10.1158\/1538-7445.am2020-ct032","article-title":"A phase 1\/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies","volume":"80","author":"Jimeno","year":"2020","journal-title":"Cancer Res."},{"key":"2025061401585573400_CIT0010","doi-asserted-by":"publisher","first-page":"e89350","DOI":"10.1371\/journal.pone.0089350","article-title":"PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One."},{"key":"2025061401585573400_CIT0011","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nri1371","article-title":"Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40","volume":"4","author":"Sugamura","year":"2004","journal-title":"Nat Rev Immunol."},{"key":"2025061401585573400_CIT0012","doi-asserted-by":"publisher","first-page":"eaat9143","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci Transl Med."},{"key":"2025061401585573400_CIT0013","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science."},{"key":"2025061401585573400_CIT0014","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest."},{"key":"2025061401585573400_CIT0015","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell."},{"key":"2025061401585573400_CIT0016","doi-asserted-by":"publisher","first-page":"e005301","DOI":"10.1136\/jitc-2022-005301","article-title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J ImmunoTher Cancer."},{"key":"2025061401585573400_CIT0017","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1158\/1078-0432.CCR-20-1830","article-title":"OX40 agonist BMS-986178 alone or in combination with nivolumab and\/or ipilimumab in patients with advanced solid tumors","volume":"27","author":"Gutierrez","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2025061401585573400_CIT0018","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1158\/1078-0432.CCR-19-3070","article-title":"Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors","volume":"26","author":"Glisson","year":"2020","journal-title":"Clin Cancer Res."},{"key":"2025061401585573400_CIT0019","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1158\/1078-0432.CCR-21-3016","article-title":"Safety and tolerability of MEDI0562, an OX40 agonist mAb, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors","volume":"28","author":"Goldman","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2025061401585573400_CIT0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-21-0845","article-title":"A phase I, open-label, dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers","volume":"28","author":"Diab","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2025061401585573400_CIT0021","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-21-4020","article-title":"First-in-human phase I study of the OX40 agonist MOXR0916 in patients with advanced solid tumors","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2025061401585573400_CIT0022","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br J Cancer."},{"key":"2025061401585573400_CIT0023","doi-asserted-by":"publisher","first-page":"17588359211039899","DOI":"10.1177\/17588359211039899","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we stand","volume":"13","author":"Leary","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2025061401585573400_CIT0024","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4161\/hv.20738","article-title":"Immunotherapy in ovarian cancer","volume":"8","author":"Mantia-Smaldone","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"2025061401585573400_CIT0025","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1200\/jco.2020.38.15_suppl.6005","article-title":"Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer","volume":"38","author":"Matulonis","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025061401585573400_CIT0026","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/ijc.27759","article-title":"Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells","volume":"132","author":"Fialova","year":"2013","journal-title":"Int J Cancer."},{"key":"2025061401585573400_CIT0027","doi-asserted-by":"publisher","first-page":"1328651","DOI":"10.3389\/fimmu.2023.1328651","article-title":"Targeting the immune microenvironment for ovarian cancer therapy","volume":"14","author":"Blanc-Durand","year":"2023","journal-title":"Front Immunol."},{"key":"2025061401585573400_CIT0028","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/2326-6066.CIR-17-0292","article-title":"Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis","volume":"5","author":"Shrimali","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"2025061401585573400_CIT0029","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/jco.2020.38.15_suppl.3092","article-title":"A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab","volume":"38","author":"Patel","year":"2020","journal-title":"J Clin Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf115\/63489011\/oyaf115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf115\/63489011\/oyaf115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T05:59:04Z","timestamp":1749880744000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf115\/8162468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf115","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf115"}}